Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CSTD002-NK
CSTD002-NK
CytoSen Therapeutics Receives Favorable Response to Pre-IND Meeting Package for Phase 2 Study in Acute Myeloid Leukemia
CP Wire
Thu, 09/27/18 - 10:09 am
CytoSen
CSTD002-NK
acute myeloid leukemia
myelodysplastic syndrome
CytoSen Therapeutics Receives Favorable Response to Pre-IND Meeting Package for Phase 2 Study in Acute Myeloid Leukemia
Thu, 09/27/18 - 09:57 am
CytoSen
CSTD002-NK
acute myeloid leukemia
myelodysplastic syndrome
